Indiana University

Pharmacophotonics, Inc.

Eli Lilly and Company

The United States Government As Represented by the Department of Veterans Affairs

The UAB Research Foundation (The University of Alabama at Birmingham)

Quark Pharmaceuticals, Inc.

Bruce Molitoris

Ruben Sandoval

Matthew J Rubin

Daniel Meier

Robert Bunch

Exing Wang

Weiming Yu

David M Bedwell

Elena Feinstein

Brian W Grinnell

Bryan Edward Jones

Shai Erlich

Svetlana Adamsky

Mark Gerard Goebl

Ruben M Sandoval, Jr

Erinn Sheridan

Mark C Wagner

A method for measuring a glomerular filtration rate in a mammalian kidney comprises a source of reporter and marker fluorescent molecules. The fluorescent molecules are introduced into the blood stream of a mammalian subject. Over a period of time, a measurement of the intensities of the reporter and marker fluorescent molecules is taken. A ratio is calculated to determine the health of the subject's kidney. This method measures volume of plasma distribution based on a fluorescence of a marker molecule relative to a fluorescence of a reporter molecule.

Renal function analysis method and apparatus

Various aspects relate to the use of C-1 gentamicin as an antibiotic effective for the treatment of a bacterial infection, a genetic disorder, or cancer in a subject.

Materials and methods for treating bacterial infections using C-1 gentamicin

Various aspects related to the preparation of congeners of the aminoglycosides gentamicin such as the congener C2 and using this compound or derivatives thereof and pharmaceutically active salts to treat diseases that involve genetic mutations which introduce a missense or premature stop codon into a gene. Still other aspects include treating human or animal patients with the gentamicin congener C2 and derivatives and pharmaceutical salt thereof to overcome, or to at least mitigate, the symptoms of disease and disorders such as some forms of Becker's or Duchenne muscular dystrophy, Hurler's Syndrome and Cystic Fibrosis that have as their etiology the presence of a premature stop codon in a gene whose proper expression is necessary for good health.

Materials and methods for treating diseases caused by genetic disorders using aminoglycosides and derivatives thereof which exhibit low nephrotoxicity

A method and apparatus for determining physiological data related to an animal, such as kidney diagnostics data, is provided. The method includes injecting a mixture of a first and a second molecule into an animal (e.g., a human patient), determining a molecular ratio of the molecules, and determining the physiological data based on the molecular ratio. The apparatus includes a number of finger receiving apertures, a light generation circuit, a light detection circuit, a pulse counting circuit, and a user interface.

Method and apparatus for kidney function analysis

The present invention relates to methods for treating chronic kidney disease (CKD) including methods for preventing or delaying onset of CKD and methods for preventing exacerbation and progression of CKD. In particular embodiments, the invention provides methods for treating a subject at risk of developing CKD comprising administering to the subject a composition comprising a) a therapeutically effective amount of at least one oligonucleotide compound which inhibits the expression of a human target gene associated with the kidney disease; and b) a pharmaceutically acceptable excipient or carrier, or mixtures thereof, thereby reducing the risk of CKD in the subject.

Methods for treating chronic kidney disease

A method for measuring a glomerular filtration rate of a mammalian subject comprises a source of reporter and marker fluorescent molecules. The fluorescent molecules are introduced into the vascular system of the mammalian subject. Over a period of time, a measurement of the intensities of the reporter and marker fluorescent molecules is taken. A ratio is calculated to determine the glomerular filtration rate.

The present invention provides a method for preventing and/or treating subjects with acute renal failure caused by a variety of conditions. The method comprises administering to the subject soluble thrombomodulin which does not activate Protein C. In conjunction with standard of care, soluble thrombomodulin that does not activate Protein C will prevent or reduce acute kidney injury and subsequent morbidity and mortality.

Treating acute renal failure with soluble thrombomodulin variants

Growing community of inventors

Indianapolis, IN, United States of America

Bruce Molitoris